Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre.
Cheema PK, Iafolla MAJ, Nematollahi M, Berco F, Kaushik D, Matthews P, Raskin WR, Perdrizet KA, Dudani S, Husain J, Balcewicz M, Kuruvilla PG, Reingold SM, Conter HJ. Cheema PK, et al. Among authors: iafolla maj. Curr Oncol. 2022 Feb 4;29(2):869-880. doi: 10.3390/curroncol29020074. Curr Oncol. 2022. PMID: 35200573 Free PMC article.
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC. Savard MF, et al. Among authors: iafolla maj. Oncologist. 2020 May;25(5):422-430. doi: 10.1634/theoncologist.2019-0605. Epub 2020 Jan 23. Oncologist. 2020. PMID: 31971318 Free PMC article.
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC. Dudani S, et al. Eur Urol. 2019 Dec;76(6):861-867. doi: 10.1016/j.eururo.2019.07.048. Epub 2019 Aug 22. Eur Urol. 2019. PMID: 31445844 Free PMC article.
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Bratman SV, et al. Among authors: iafolla maj. Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3. Nat Cancer. 2020. PMID: 35121950
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Al-Ezzi EM, Alqaisi HA, Iafolla MAJ, Wang L, Sridhar SS, Sacher AG, Fallah-Rad N, Jiang DM, Watson GA, Catton CN, Warde PR, Hamilton RJ, Fleshner NE, Zlotta AR, Hansen AR. Al-Ezzi EM, et al. Among authors: iafolla maj. Cancer Med. 2021 Sep;10(17):5775-5782. doi: 10.1002/cam4.4125. Epub 2021 Jul 13. Cancer Med. 2021. PMID: 34254464 Free PMC article.
26 results